Home / Business and Economy / Pathkey and Armstrong Clinical Partner to Optimize Clinical Trial Design
Pathkey and Armstrong Clinical Partner to Optimize Clinical Trial Design
12 Nov
Summary
- Pathkey and Armstrong Clinical enter master collaboration agreement
- Partnership leverages Pathkey's AI tech and Armstrong's early-phase expertise
- Aims to improve clinical development outcomes, reduce costs, and expedite market entry
On November 12, 2025, Pathkey, a leading predictive AI technology company, announced a master collaboration agreement with Armstrong Clinical, a clinical development consultancy based in Melbourne, Australia. The partnership aims to leverage Pathkey's advanced analytics with Armstrong Clinical's expertise in early-phase study design to improve clinical development outcomes across the life sciences sector.
Through this initiative, the companies intend to help biotech and research sponsors design smarter, more resilient studies from the beginning, increasing the probability of success throughout the entire development lifecycle. The collaboration is also expected to deliver greater capital efficiency and transparency for investors, as well as stronger evidence to support trial approvals for health systems and regulators.
Pathkey's executive chairman, Damon Rasheed, stated that the earliest stages of clinical development often determine whether a therapy ever reaches patients, making Armstrong Clinical's human expertise in early-phase strategy the perfect complement to Pathkey's predictive AI technology. Armstrong Clinical's founder, Dr. Bradley Joblin, echoed this sentiment, expressing that the partnership will bring a new layer of data-driven intelligence to their process, delivering greater certainty, efficiency, and confidence in early-phase strategy for their clients.
